Josep Villanueva
jvillanueva@vhio.net
Lloc actual
- Cap d’equip dins del Grup de Proteòmica
- També forma part del consell editorial del Journal of Proteomics.
- Revisor ad hoc habitual de: Journal of Chromatography A; Journal of Proteome Research; Journal of Proteomics; Molecular & Cellular Proteomics; Proteomics; Rapid Communications in Mass Spectrometry.
Formació acadèmica
- Investigador sènior amb Paul Tempst, 2005-2009. Memorial Sloan-Kettering Cancer Center (MSKCC), Nova York, EUA.
- Becari postdoctoral amb Paul Tempst, 2002-2005. Memorial Sloan-Kettering Cancer Center (MSKCC), Nova York, EUA.
- Becari postdoctoral amb Xavier Avilés, 2000-2002. Universitat Autònoma de Barcelona (UAB), Barcelona, Espanya.
- Doctorat en Bioquímica i Biologia Molecular amb Xavier Avilés i Enrique Querol, 2000. Universitat Autònoma de Barcelona (UAB), Barcelona, Espanya.
- Llicenciat en Bioquímica, 1995. Universitat Autònoma de Barcelona (UAB), Barcelona, Espanya.
Àrees de recerca
- Descobriment de biomarcadors específics per a tumors secretors en càncer de mama mitjançant proteòmica.
- Establiment de vies de secreció-activació proteòmica en vies de senyalització associades a la tumorogènesi.
- Caracterització del microentorn del tumor mitjançant el perfil proteòmic dels secretomes.
Premis i beques
- Premi de Recerca per a llicenciats excel·lents de la Universitat Autònoma de Barcelona (UAB), Espanya, 2005.
- Beca de recerca per a llicenciats de la Universitat Autònoma de Barcelona (UAB), Espanya, 1996.
- Beca postdoctoral de curta durada del Laboratori Europeu de Biologia Molecular (EMBL), Alemanya, 2002.
- U24 CA126485-01 «Tecnologia clínica proteòmica per a l’avaluació del càncer», Institut Nacional del Càncer del NIH (2006-2011). Funcions: coinvestigador
- Projecte Miguel Servet. «Perfils proteòmics quantitatius de secretomes per al descobriment de fàrmacs diana». ISCIII (Institut de la Salut Carlos III) (2009-2011). Funcions: investigador principal
- Institut de la Salut Carlos III (FIS).«Vies dels secretomes en el descobriment de biomarcadors en el càncer de mama» (2010-2012).
- Beca de Reintegració Internacional Marie Curie. «Vies dels secretomes en el descobriment de biomarcadors en el càncer de mama» (2010-2012).
Publicacions científiques més rellevants
- Juliachs M, Pujals M, Bellio C, Meo-Evoli N, Duran JM, Zamora E, Parés M, Suñol A, Méndez O, Sánchez-Pla A, Canals F, Saura C, Villanueva J. Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer. Cancers (Basel). 2022 Aug 10;14(16):3858.
- Bellio C, Emperador M, Castellano P, Gris-Oliver A, Canals F, Sánchez-Pla A, Zamora E, Arribas J, Saura C, Serra V, Tabernero J, Littlefield BA, Villanueva J. GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells. Cancers (Basel). 2022 May 23;14(10):2562.
- Pujals M, Resar L, Villanueva J. HMGA1, Moonlighting Protein Function, and Cellular Real Estate: Location, Location, Location! Biomolecules. 2021 Sep 9;11(9):1334.
- Granado-Martínez P, Garcia-Ortega S, González-Sánchez E, McGrail K, Selgas R, Grueso J, Gil R, Naldaiz-Gastesi N, Rhodes AC, Hernandez-Losa J, Ferrer B, Canals F, Villanueva J, Méndez O, Espinosa-Gil S, Lizcano JM, Muñoz-Couselo E, García-Patos V, Recio JA. STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation. Commun Biol. 2020 Jul 9;3(1):366.
- Bellio C, Villanueva J. Hitting the brakes on autophagy for overcoming acquired resistance in triple negative breast cancer. Ann Transl Med. 2020 Jul;8(14):848.
- Méndez O, Pérez J, Soberino J, Racca F, Cortés J, Villanueva J. Clinical Implications of Extracellular HMGA1 in Breast Cancer. Int J Mol Sci. 2019. 20(23), 5950.
- Méndez O, Villanueva J. Challenges and opportunities for cell line secretomes in cancer proteomics. Proteomics Clin Appl. 2015;9(3-4):348-357.
- Katsila T, Juliachs M, Gregori J, Macarulla T, Villarreal L, Bardelli A, Torrance C, Elez E, Tabernero J, Villanueva J. Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. Clin. Cancer Res. 2014 Dec; 20(24): 6346-56
- Villarreal L, Méndez O, Salvans C, Gregori J, Baselga J, Villanueva J*. Unconventionalsecretion is a major contributor of cancer cell line secretomes. Mol Cell Proteomics. 2013, 12(5):1046-60.
- Gregori J, Méndez O, Katsila T, Pujals M, Salvans C, Villarreal L, Arribas J, Tabernero J, Sánchez A, Villanueva J. Enhancing the Biological Relevance of Secretome-Based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion. J. Proteome Res. 2014 Jul;
- Gregori J, Villarreal L, Sánchez A, Baselga J, Villanueva J. An effect size filter improves the reproducibility in spectral counting-based comparative proteomics. J Proteomics 2013 Dec; 95: 55-65
- Gregori J, Villarreal L, Méndez O, Sánchez A, Baselga J, Villanueva J. Batch effects correction improves the sensitivity of significance tests in spectral counting-based comparative discovery proteomics. J Proteomics 2012 Jul; 75(13): 3938-51
- Lawlor K, Nazarian A, Lacomis L, Tempst P, Villanueva J*. Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. J Proteome Research. 2009. 8(3):1489-503.
Totes les publicacions
- Juliachs M, Pujals M, Bellio C, Meo-Evoli N, Duran JM, Zamora E, Parés M, Suñol A, Méndez O, Sánchez-Pla A, Canals F, Saura C, Villanueva J. Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer. Cancers (Basel). 2022 Aug 10;14(16):3858.
- Bellio C, Emperador M, Castellano P, Gris-Oliver A, Canals F, Sánchez-Pla A, Zamora E, Arribas J, Saura C, Serra V, Tabernero J, Littlefield BA, Villanueva J. GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells. Cancers (Basel). 2022 May 23;14(10):2562.
- Zacarias-Fluck MF, Morancho B, Vicario R, Luque Garcia A, Escorihuela M, Villanueva J, Rubio IT, Arribas J. Effect of cellular senescence on the growth of HER2-positive breast cancers. J. Natl. Cancer Inst. 2015 May; 107(5)
- Morancho B, Martínez-Barriocanal Á, Villanueva J, Arribas J. Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence. Breast Cancer Res. 2015; 17: 106
- Katsila T, Juliachs M, Gregori J, Macarulla T, Villarreal L, Bardelli A, Torrance C, Elez E, Tabernero J, Villanueva J. Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. Clin. Cancer Res. 2014 Dec; 20(24): 6346-56
- Nazarian A, Lawlor K, Yi SS, Philip J, Ghosh M, Yaneva M, Villanueva J, Saghatelian A, Assel M, Vickers AJ, Eastham JA, Scher HI, Carver BS, Lilja H, Tempst P. Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer. Mol. Cell Proteomics 2014 Nov; 13(11): 3082-96
- Gregori J, Méndez O, Katsila T, Pujals M, Salvans C, Villarreal L, Arribas J, Tabernero J, Sánchez A, Villanueva J. Enhancing the Biological Relevance of Secretome-Based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion. J. Proteome Res. 2014 Jul;
- Segura V, Medina-Aunon JA, Mora MI, Martínez-Bartolomé S, Abian J, Aloria K, Antúnez O, Arizmendi JM, Azkargorta M, Barceló-Batllori S, Beaskoetxea J, Bech-Serra JJ, Blanco F, Monteiro MB, Cáceres D, Canals F, Carrascal M, Casal JI, Clemente F, Colomé N, Dasilva N, Díaz P, Elortza F, Fernández-Puente P, Fuentes M, Gallardo O, Gharbi SI, Gil C, González-Tejedo C, Hernáez ML, Lombardía M, Lopez-Lucendo M, Marcilla M, Mato JM, Mendes M, Oliveira E, Orera I, Pascual-Montano A, Prieto G, Ruiz-Romero C, Sánchez del Pino MM, Tabas-Madrid D, Valero ML, Vialas V, Villanueva J, Albar JP, Corrales FJ. Surfing transcriptomic landscapes. A step beyond the annotation of chromosome 16 proteome. J. Proteome Res. 2014 Jan; 13(1): 158-72
- Gregori J, Villarreal L, Sánchez A, Baselga J, Villanueva J. An effect size filter improves the reproducibility in spectral counting-based comparative proteomics. J Proteomics 2013 Dec; 95: 55-65
- Angelini PD, Zacarias Fluck MF, Pedersen K, Parra-Palau JL, Guiu M, Bernadó Morales C, Vicario R, Luque-García A, Navalpotro NP, Giralt J, Canals F, Gomis RR, Tabernero J, Baselga J, Villanueva J, Arribas J. Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence.Cancer Res. 2013 Jan; 73(1): 450-8
- Gregori J, Villarreal L, Méndez O, Sánchez A, Baselga J, Villanueva J. Batch effects correction improves the sensitivity of significance tests in spectral counting-based comparative discovery proteomics. J Proteomics 2012 Jul; 75(13): 3938-51
- Sánchez A, Villanueva J. PI3K-based molecular signatures link high PI3K pathway activity with low ER levels in ER+ breast cancer. Expert Rev Proteomics 2010 Dec; 7(6): 819-21
- Villanueva J, Nazarian A, Lawlor K, Tempst P. Monitoring peptidase activities in complex proteomes by MALDI-TOF mass spectrometry. Nat Protoc 2009; 4(8): 1167-83
- Lawlor K, Nazarian A, Lacomis L, Tempst P, Villanueva J. Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. J. Proteome Res. 2009 Mar; 8(3): 1489-503
- Villanueva J, Nazarian A, Lawlor K, Yi SS, Robbins RJ, Tempst P. A sequence-specific exopeptidase activity test (SSEAT) for “functional” biomarker discovery. Mol. Cell Proteomics 2008 Mar; 7(3): 509-18
- Villanueva J, Philip J, DeNoyer L, Tempst P. Data analysis of assorted serum peptidome profiles. Nat Protoc 2007; 2(3): 588-602
- Villanueva J, Lawlor K, Toledo-Crow R, Tempst P. Automated serum peptide profiling. Nat Protoc 2006; 1(2): 880-91
- Villanueva J, Martorella AJ, Lawlor K, Philip J, Fleisher M, Robbins RJ, Tempst P. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol. Cell Proteomics 2006 Oct; 5(10): 1840-52
- Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sánchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 2006 Jan; 116(1): 271-84
- Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, Tempst P. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem. 2004 Mar; 76(6): 1560-70
